Skip to main content

Peer Review reports

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Original Submission
18 Oct 2019 Submitted Original manuscript
5 Mar 2020 Author responded Author comments - Thomas Decker
10 Mar 2020 Author responded Author comments - Thomas Decker
10 Feb 2020 Reviewed Reviewer Report - Marcus Schmidt
23 Feb 2020 Reviewed Reviewer Report - Poonam Aggarwal
Resubmission - Version 2
5 Mar 2020 Submitted Manuscript version 2
Publishing
12 Mar 2020 Editorially accepted
6 Apr 2020 Article published 10.1186/s12885-020-06747-y

You can find further information about peer review here.

Back to article page